Objectives. Internal organ involvement reduces the life expectancy of SSc patients. Cardiopulmonary manifestations are currently the primary cause of death. We aimed to perform a systematic review and meta-analysis to define more precise effect estimates of different cardiopulmonary manifestations and to verify trends in the mortality of SSc.
Introduction
SSc is an autoimmune disease characterized by multiorgan involvement resulting in significant morbidity and mortality. During the last decades, there was a change in the mortality spectrum of SSc patients caused by the development of effective therapeutic opportunities and the regular screening of patients [1] . Recent cohorts report that currently the primary cause of death in scleroderma is related to pulmonary and cardiac disease [25] .
However, the prevalence and prognostic significance of cardiopulmonary manifestations of SSc vary widely depending on the period of observation, methods of assessment and the geographic area of study. Although survival in patients with SSc improved in the past several decades, it remained considerably reduced compared with matched populations [4, 616] .
Estimates of overall survival, as well as survival by disease subtypes are important to predict the course of the disease and to detect its changing natural history. Furthermore, these data are invaluable for evaluating the health impact of this disease on the population [17] .
In our current review and meta-analysis, we collected and summarized the available evidence regarding the incidence and prognostic significance of cardiopulmonary manifestations in SSc in order to achieve better statistical power, define more precise effect estimates of different internal organ manifestations and verify trends in mortality of SSc.
Methods

Search strategy
We performed a systematic review of the available publications according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [18] for conducting meta-analyses of observational studies. PubMed, Web of Science with Conference Proceedings and the Cochrane Central Register of Controlled Trials databases were searched for relevant articles published between January 1960 and July 2010. Search key words included various combinations of scleroderma OR systemic AND sclerosis, together with the medical subject headings (MeSH) of the following terms: mortality, survival, outcome and prognosis. No language restriction was used. We also searched the reference lists of relevant studies, reviews, editorials and letters. In case of incomplete reporting, individual authors were contacted.
Selection criteria
We selected all relevant studies that met the following inclusion criteria:
(i) Studies that recruited SSc patients regardless of specific organ manifestation. In order to avoid bias from overrepresentation of patients with one or another organ-specific manifestation or complication, typically studies reporting scleroderma renal crisis (SRC) or pulmonary hypertension patient cohorts were excluded. (ii) Reports of prospective or retrospective SSc cohorts that allow assessment of the impact of organ manifestations on mortality. Studies presenting the overall survival of SSc patients were only accepted if they reported mortality compared with an ageand gender-adjusted background population, i.e. in the form of a standardized mortality ratio (SMR). The primary clinical outcome of interest was overall mortality, evaluated at the longest available follow-up.
Data abstraction
Selection and data abstraction were done independently by two reviewers (A.K. and A.V.) on pre-specified, structured data-collection forms. Disagreements were resolved by consensus and discussion with a third party (R.F.). The Newcastle Ottawa quality scoring system was used for quality assessment of the cohort reports [19] . Standard definition for cardiac involvement included pericarditis verified by echocardiography, recurrent arrhythmia and/or conduction abnormalities on ECG, or clinical signs of heart failure. Pulmonary arterial hypertension (PAH) was diagnosed by standard right heart catheterization. Interstitial pulmonary involvement was defined as bibasilar fibrosis on the chest X-ray, or lung function test abnormalities with reduction of the forced vital capacity or CO diffusing capacity. Renal involvement was defined as the presence of SRC, with malignant hypertension and rapidly progressing renal failure.
Predefined sensitivity and subgroup analyses were performed between low-and high-quality studies (i.e. studies with quality score under and over the median), studies using standardized vs non-standardized criteria for organ involvement, recent and older studies, and among studies with shorter or longer follow-up. Furthermore, metaregression analyses of the mortality risk and other study characteristics, including study enrolment and publication dates, length of follow-up, study size and proportion of genders and different SSc subsets, were performed in order to identify possible sources of heterogeneity.
Results
Study selection
Our search resulted in 802 citations. These included reviews and articles that did not meet our inclusion criteria. After abstract evaluation, 90 potentially appropriate studies were found. Following the exclusion of possible duplications and organ-specific manifestation-based cohorts, 18 articles (including a total number of 12 829 patients) were selected for full-text analysis and data extraction (Fig. 1) .
Out of these, 7 were prospective and 11 were retrospective trials. Eleven studies provided data about the risk associated with cardiac manifestations, 12 studies reported data on pulmonary involvement, 6 presented data on PAH and another 12 investigated the impact of renal involvement. The mean age of patients was 47.9 years. On average, 83.7% of the subjects were female. The mean rate of dcSSc was 38.1%. Antibody serology results were reported in 13 studies. Characteristics of the included studies are presented in Table 1 .
Clinical results
Frequencies of different visceral manifestations and causes of death, including causes determined to be SSc related, are presented in Table 2 . There was a significant association between the publication year of the studies and the reported SMRs associated with SSc (R 2 = 0.4295, P = 0.04), indicating significantly better survival in the more recent studies (Fig. 2 ). Meta-regression analyses performed with the number of patients, the proportion of female gender, the proportion of cutaneous subsets, the mean age of the subjects, the length of the follow-up period and the date of patient enrolment showed no significant effect on the SMR (R 2 = 0.03, Meta-regression analysis of the published HRs and the year of publication found a significant trend for improvement in which the survival difference between the cutaneous subtypes grew smaller over the years (R 2 = 0.41. Fig. S1 , available as supplementary data at Rheumatology Online). Four studies provided HR data related to arrhythmia or ECG changes [8, 12, 16, 20] . Scussel-Lonzetti et al. [12] , specified these as right or left bundle branch block, left anterior fascicular block, sinus bradycardia and supraventricular or ventricular dysrhythmia. Assassi et al. [20] and Joven et al. [16] provided HRs for patients with arrhythmia and Bryan et al. [8] provided HRs for cases with abnormal ECG, without further specification. Of note, Joven et al. [16] published HRs only for the limited cutaneous subgroup and found no statistically significant effect either on the outcome of the dSSc cases or on that of the overall cohort. The cumulative HR for mortality of these studies was 3.52 (2.48, 4.99) (see supplementary Fig. S2 , available as supplementary data at Rheumatology Online). Outcomes showed significant heterogeneity among studies. However, similar effects were consistently shown in the subgroup analyses, which confirm the robustness of our data (Table 3) .
Discussion
Prior to this meta-analysis, numerous observational studies have highlighted that different visceral manifestations have a significant impact on the outcome of SSc [2, 3, 2123] . A variable combination of organ damage or, less frequently, severe single organ involvement is responsible for SSc morbidity and mortality. The functional impairment of different organs shows variable, frequently subclinical progression and overlap, which makes the long-term outcome of SSc extremely unpredictable [24] .
Our study confirmed the well-known fact that patients with cardiopulmonary involvement in SSc are at a higher risk of death [13, 5] . Intriguingly, the HRs of the different organ manifestations were in a very similar range: HR 2.39 (95% CI 1.64, 3.50) for renal and a cumulative HR of 2.95 (95% CI 2.44, 3.56) for cardiopulmonary manifestations. Additionally, meta-regression of studies providing SMRs demonstrates a trend for improvement over the last decades in which the life expectancy of SSc patients approaches that of the general population. Moreover, we found a trend of decreasing difference in survival between limited and diffuse cutaneous subgroups.
Advances in terms of better and earlier diagnosis as well as more efficient treatment of internal organ manifestations may be the most important contributing factors to the improved outcome of SSc. In a study-level meta-analysis, however, separation of these two possible contributors is limited due to the lack of generally accepted and consistently reported objective measures that could be used for correction regarding disease status. Furthermore, underreporting data concerning management strategies impedes assessment of the outcome respective to treatment. We found no association among the mean age of the cohorts and their outcome; supporting studies from the examined period had similar diagnostic backgrounds. Consequently, the observed trends for improved outcome may be attributable to the availability of more effective therapies. However, survival of patients with SSc remains considerably decreased compared with age-and sex-matched populations [616] .
Prior to the era of angiotensin-converting enzyme (ACE) inhibitors, renal disease, specifically SRC, was the most Although ACE inhibitors and dialysis are now readily available, SRC continues to be associated with poor survival, even in recently published reports [27] . Our data underlines that renal involvement still plays an important role in SSc mortality, and indicates that further efforts to improve the therapy of this complication are needed. The understanding that PAH has a major impact on the prognosis of SSc prompted a wide range of initiatives to remodel diagnostic and therapeutic protocols. Screening programmes for SSc patients demonstrably improve the diagnosis of PAH, and detection of individuals with lessdeveloped disease and novel vasodilatory drugs improve the prognosis of SSc patients with PAH [28, 29] . In contrast to patients treated historically with heart glycosides, diuretics and prostanoids, patients treated in the current era have improved survival [3032] .
Recent studies have demonstrated that pulmonary vascular and interstitial involvement is independent in progression and in determining the outcome of disease [33, 34] . Pulmonary fibrosis is a major factor in mortality and morbidity [13, 33] . Early detection and cyclophosphamide (CPH) treatment may impede its progression and hamper the evolution to end-stage pulmonary insufficiency. CPH is reported to improve pulmonary function and to have a beneficial effect on survival. Nevertheless, the treatment of pulmonary fibrosis remains a challenge, with no clear efficacy of the immunosuppressive regimen [5, 35, 36] . Due to the lack of reliable reporting of treatment strategies, our analysis was underpowered to draw further conclusions in this area.
During the analysis of the survival studies we were confronted with large differences in the methodology, standard diagnostic methods and definitions of organ involvements. These discrepancies may reflect true variation in the disease progression, or may be related to methodological differences inherent in the different local examination strategies, or the classification of different disease manifestations. Several high-quality epidemiological studies even omitted assessment of cardiac involvement due to incomplete documentation and difficulty in attributing cardiac disease to SSc rather than other causes [17] . Definitions for renal involvement and pulmonary fibrosis were uniform in most of the reports. The definition of cardiac involvement and (in some studies) grouping of the otherwise generally accepted definition of pulmonary hypertension with either pulmonary or cardiac manifestations differed considerably. This points towards an important controversy, that despite the prevalence of cardiac and pulmonary causes of death among SSc patients, we lack generally accepted criteria, diagnostic methods and consensus cut-offs for cardiac organ involvement [37] . Proper characterization of high-risk patients requires the establishment of appropriate treatment strategies and facilitation of further improving care in SSc. Indeed, coronary heart disease in the form of coronary artery sclerosis and/or microvascular disease and pulmonary hypertension can be found frequently in combination in symptomatic SSc patients, representing a diagnostic and prognostic challenge [24] . The trend for improving survival in SSc also implies that in the ageing population of SSc patients, we meet a higher frequency of coronary heart disease. Furthermore, clinical presentation of coronary atherosclerosis is atypical in this patient group, and coronary abnormalities may be found among symptom-free patients [38, 39] . Sometimes in individual cases it is difficult to determine whether the specific symptoms are attributable to SSc or to independent cardiac disease. Analogously, symptoms of cardiac manifestations, pulmonary disease and PAH-related cor pulmonale overlap and render retrospective analysis very difficult.
Although PAH is primarily a disorder of the regulation of pulmonary microcirculation, its symptoms are mainly due to the consequent right ventricular strain, cor pulmonale and congestive heart failure. In addition, the presence of coronary disease may mimic and interfere with the symptoms of PAH in patients with SSc. In our recent study we performed left and right heart catheterization among symptomatic SSc cases; pure PAH without coronary disease was a rare finding, which affected only 10% of cases [24] . This supports the idea that the invasive approach, including conventional or CT angiography, is reasonable in order to properly characterize the nature of right and left heart involvement.
In our analysis, the impact of heart disease on the mortality of SSc was similar to the above-mentioned major organ manifestations. It has been hypothesized that primary myocardial involvement (SScMI), characterized by contractile dysfunction, conduction disturbances and arrhythmia, is provoked by ischaemia, however, the underlying mechanism is not fully elucidated [40] . The prevalence of left ventricular dysfunction was estimated to be 5.4% among the participants of the EULAR Scleroderma Trial and Research group (EUSTAR) registry [37] . A summary from the same database reports that arrhythmia was the primary cause of death in 6%, while left or combined ventricular failure accounted for 5% of deaths [41] .
Restriction of coronary adaptation reported by several invasive and non-invasive studies may be the consequence of damage at the level of the capillary field, which is provoked by ischaemia and maintains a consequent compensatory state with accelerated coronary flow even at rest. The maximal coronary flow being unchanged, this may result in a blunted coronary flow reserve (CFR). This explanation may link reduced CFR and patchy myocardial fibrosis, together giving an explanation of changes that lead to wall motion abnormalities, arrhythmia, and in severe cases to congestive heart failure [42] . We found a cumulative HR for patients with arrhythmia very close to the HR of cardiac involvement. This may imply that the presence of arrhythmia as a risk marker is similar to the presence of cardiac involvement in general.
The use of calcium channel blockers has recently been found to be protective against left ventricular Data are presented as HR (95% CI). *P < 0.05, **P < 0.01, ***P < 0.0001, ****P = 0.05. QS: quality score.
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Impact of cardiopulmonary manifestations in SSc dysfunction in a large international casecontrol study [37] . In this study, decreased myocardial function showed an association with digital ulcers, while in another study vasodilatory treatment had a protective effect against ulcer formation [43] . These data suggest that, at the level of microcirculation, a common mechanism may lead to the different manifestations. The short-term beneficial effect of vasodilator treatment, in terms of better myocardial perfusion and improvement in contractility, also supports the concept that reversible ischaemia plays a possible role in myocardial involvement [4447] . Longterm effects of vasodilators, however, remain to be determined, as only indirect evidence supports this hypothesis, and controlled studies are warranted before drawing firm conclusions [48] . Interpretation of survival data from various centres has some inherent limitations. As its annual incidence is under 10 per million population, SSc is a rare disease. Inevitably, therefore, expertise in managing patients is concentrated at tertiary centres. Such centres, however, are likely to receive the more severe cases, and thus their experience, reflected in the publications, may overestimate the true mortality of SSc [49] . Another possible limiting factor is the left censorship incorporated in patient recruitment. Retrospective trials may be less influenced, but in prospective registries and in cross-sectional studies, inclusion of the prevalent cases with possibly less severe disease and better prognosis may falsely improve the survival data of the cohort. A solution could be to separate prevalent and incident cases, an approach that is only rarely attempted [3] . Although both types of cases may still be affected by referral biases, prevalent cases are more vulnerable.
The meta-analysis included observational studies, which are usually unbalanced with regard to the baseline clinical characteristics of the patients. Observational studies may better reflect real-world practice, with data covering the entire patient spectrum as compared with randomized studies that may exclude the seriously ill and advanced cases with limited life expectancy. Furthermore, lack of monitoring of drug compliance, underreporting of negative results and incomplete follow-up make interpretation of observational cohort data more difficult and more likely to carry ascertainment biases. Thus data were pooled with logarithmic transformation according to a random-effect model via generic inverse-variance weighting, which is a more appropriate method for observational studies. A further limitation is that the patients were possibly not treated uniformly, and data regarding treatment protocols are scarcely reported. This fact impedes comparative hypothesis generation regarding the effectiveness of different treatment strategies.
In conclusion, this meta-analysis confirms that patients with cardiopulmonary involvement are at higher risk for poor outcome. Cardiopulmonary involvement is found to be the major cause of death. Alleviation of diseasespecific complications resulted in the trend that the mortality profile of scleroderma patients now approaches that of the general population. Efforts aiming to better diagnose and treat cardiac disease in scleroderma patients can be validated on the available epidemiological data.
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